With the world’s best-selling drug now facing direct biosimilar competition, AbbVie says it is confident its robust pipeline will deliver double-digit growth going forward. In 2018, the first biosimilar versions of Humira (adalimumab) were launched in Europe and other non-US markets. Meanwhile in October, Sandoz became the third firm to receive US Food and Drug Administration (FDA) approval for a Humira biosimilar. It is, therefore, fair to say sales of the world’s top selling drug – Humira clocked in sales…